133 related articles for article (PubMed ID: 38286107)
1. Long-term efficacy and safety of perampanel as an add-on therapy in patients with epilepsy.
Arai Y; Inaji M; Shimizu K; Kondo S; Hashimoto-Fujimoto S; Kiyokawa J; Kawano Y; Yamamoto S; Maehara T
Epilepsy Res; 2024 Feb; 200():107307. PubMed ID: 38286107
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of mono- and add-on perampanel in pediatric patients with epilepsy: Experience from a single-center retrospective study.
Li Y; Guo HL; Hu YH; Wang J; Zhang YY; Huang J; Xu J; Chen J; Lu XP; Chen F
Epilepsia Open; 2024 Feb; 9(1):268-277. PubMed ID: 37943144
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of perampanel as the first add-on therapy for children with epilepsy: A real-world multicenter prospective observational study.
Mai J; Li H; He Y; Huang T; Lin C; Lan S; Xiao X; He S; Lu X; Chen L; Li B; Luo X; Wang H; Liao J; Cao D
Seizure; 2024 Apr; 117():44-49. PubMed ID: 38308908
[TBL] [Abstract][Full Text] [Related]
4. Electro-clinical analysis of epilepsy patients with generalized seizures on adjunctive perampanel treatment.
Montoya Gutiérrez FJ; Díaz Román M; Cerveró Albert D
Epilepsy Res; 2020 Sep; 165():106378. PubMed ID: 32622260
[TBL] [Abstract][Full Text] [Related]
5. PERPRISE: A prospective non-interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic-clonic seizures: First interim analysis.
Steinhoff BJ; Goldmann T; Kockelmann E; Winter Y;
Epilepsia Open; 2024 Jun; 9(3):926-939. PubMed ID: 38017663
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON).
Abril Jaramillo J; Estévez María JC; Girón Úbeda JM; Vega López Ó; Calzado Rivas ME; Pérez Díaz H; García Martín G; Vila Herrero E; Chamorro-Muñoz M; Vázquez F; De la Fuente C; Redondo L; Peláez N; Santágueda P; Rodríguez Uranga JJ
Epilepsy Behav; 2020 Jan; 102():106655. PubMed ID: 31812902
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs.
Santamarina E; Bertol V; Garayoa V; García-Gomara MJ; Garamendi-Ruiz I; Giner P; Aranzábal I; Piera A; Arcos C; Esteve P; Marinas A; García-Escrivá A; Viloria-Alebesque A; Loro FA; de Tienda AP; Olivan JA; Bonet M; Dávila-González P; Sivera R; Molins A; Sansa G; Roche JC; Martínez AB; Monteagudo S; Casadevall T
Seizure; 2020 Dec; 83():48-56. PubMed ID: 33096456
[TBL] [Abstract][Full Text] [Related]
8. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
[TBL] [Abstract][Full Text] [Related]
9. Perampanel add-on therapy for drug-refractory epilepsy: A single-center retrospective study based on 6-month treatment outcomes in Central China.
Zhang Y; Han X; Zhao P; Wang B; Li M; Zhao T; Wang N; Chen Y
Epilepsy Behav; 2022 Apr; 129():108617. PubMed ID: 35219170
[TBL] [Abstract][Full Text] [Related]
10. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.
Resnick T; Patten A; Ngo LY; Malhotra M
Epilepsy Behav; 2022 Mar; 128():108528. PubMed ID: 35078116
[TBL] [Abstract][Full Text] [Related]
11. Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study.
Rodríguez-Osorio X; Lema-Facal T; Rubio-Nazábal E; Castro-Vilanova MD; Pato-Pato A; Abella-Corral J; Corredera E; López-Ferreiro A; Puy-Núñez A; López-González FJ
Epilepsy Res; 2021 May; 172():106570. PubMed ID: 33621770
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive Perampanel in Older Patients With Epilepsy: A Multicenter Study of Clinical Practice.
Lattanzi S; Cagnetti C; Foschi N; Ciuffini R; Osanni E; Chiesa V; Dainese F; Dono F; Canevini MP; Evangelista G; Paladin F; Bartolini E; Ranzato F; Nilo A; Pauletto G; Marino D; Rosati E; Bonanni P; Marrelli A
Drugs Aging; 2021 Jul; 38(7):603-610. PubMed ID: 34075567
[TBL] [Abstract][Full Text] [Related]
13. A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy.
Maguire M; Ben-Menachem E; Patten A; Malhotra M; Ngo LY
Epilepsy Behav; 2022 Jan; 126():108483. PubMed ID: 34953337
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
Steinhoff BJ; Patten A; Williams B; Malhotra M
Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
[TBL] [Abstract][Full Text] [Related]
15. A post hoc analysis of the long-term safety and efficacy of perampanel in Asian patients with epilepsy.
Inoue Y; Kaneko S; Hsieh PF; Meshram C; Lee SA; Aziz ZA; Nabangchang C; Dash A
Epilepsia; 2019 Mar; 60 Suppl 1():60-67. PubMed ID: 30869167
[TBL] [Abstract][Full Text] [Related]
16. Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence.
Yamamoto T; Gil-Nagel A; Wheless JW; Kim JH; Wechsler RT
Epilepsy Behav; 2022 Nov; 136():108885. PubMed ID: 36150304
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies.
Piña-Garza JE; Villanueva V; Rosenfeld W; Yoshinaga H; Patten A; Malhotra M
Epilepsy Behav; 2022 Oct; 135():108901. PubMed ID: 36122531
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study.
Wang Q; Xu Y; Chen Y; Wu X; Ge Y; Zhu G
Epilepsy Behav; 2022 Nov; 136():108937. PubMed ID: 36215830
[TBL] [Abstract][Full Text] [Related]
19. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
20. Value of drug level concentrations of brivaracetam, lacosamide, and perampanel in care of people with epilepsy.
Hentschel M; Stoffel-Wagner B; Surges R; von Wrede R; Dolscheid-Pommerich RC
Epilepsia; 2024 Mar; 65(3):620-629. PubMed ID: 38158709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
